Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Rising Oral Doses of BI 1569912 in Healthy Male Subjects
NCT04978506Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1569912 (9 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Number of Subjects With Drug-related Adverse Events. Started Sep 2021; status: completed.
02
Drugs
BI 1569912
Beyond the preview
Go deeper on NCT04978506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978506.